Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
AssigneeBoehringer Ingelheim Animal Health USA Inc.
InventorsMichel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz, Aemro Kassa
Life of this patent
Estimating the term…
Abstract
The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
Claims20
A vaccine comprising a recombinant herpesvirus of turkeys (HVT) vector, wherein the HVT vector comprises a first heterologous polynucleotide coding for and expressing an Infectious Bursal Disease Virus (IBDV) viral protein 2 (VP2) antigen and a second heterologous polynucleotide coding for and expressing a Newcastle Disease Virus Fusion Protein (NDV-F) antigen,
- wherein the IBDV VP2 antigen has at least 85% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, and wherein the NDV-F antigen has at least 85% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5;
- wherein the two heterologous polynucleotides are inserted into one locus in a non-essential region of the HVT genome selected from the group consisting of intergenic region 1 locus, intergenic region 2 locus, intergenic region 3 locus, UL43 locus, US10 locus, US2 locus, and SORF3/US2 locus;
- wherein the two heterologous polynucleotides are linked by internal ribosome entry site (IRES);
- and
- wherein the expression of the two heterologous polynucleotides is driven by a mouse cytomegalovirus (mCMV) immediate early (IE) promoter or human cytomegalovirus (hCMV) IE promoter.
Dependencies are inferred from the claim text.